Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …

It has been more than three decades since the first monoclonal antibody was approved by
the United States Food and Drug Administration (US FDA) in 1986, and during this time …

Checkpoint inhibitor pneumonitis (CIP) is an immune-related adverse event that can occur
after initiation of anti–programmed death 1/programmed death ligand 1 immune checkpoint …

The lack of response to treatment in most lung cancer patients suggests the value of
broadening the benefit of anti–PD-1/PD-L1 monotherapy. Judicious dosing of …

Immune checkpoint inhibitors (ICIs) are newer, immunotherapy-based drugs that have been
shown to improve survival in advanced non-small cell lung cancer (NSCLC). Unlike …

Effective immunotherapy options for patients with non–small cell lung cancer (NSCLC) are
becoming increasingly available. The immunotherapy focus has been on tumor-infiltrating T …

Small cell lung cancer (SCLC) is an aggressive tumor characterized by rapid doubling time
and high propensity for early development of disseminated disease. Although most patients …

Simple Summary Initial clinical observations revealed strikingly longer follow-up for
metastatic non-small-cell lung cancer (NSCLC) patients receiving nivolumab infusions …

Approximately one third of all lung cancer patients in East Asia are never-smokers.
Furthermore, the proportion of lung cancer in never smokers (LCINS) has been increasing …

Background Tumor orchestrated metabolic changes in the microenvironment limit
generation of anti-tumor immune responses. Availability of arginine, a semi-essential amino …